

# Martijn P W Intven

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4822162/publications.pdf>

Version: 2024-02-01

73  
papers

2,423  
citations

186265  
28  
h-index

214800  
47  
g-index

74  
all docs

74  
docs citations

74  
times ranked

2645  
citing authors

#	ARTICLE	IF	CITATIONS
1	Frailty and health related quality of life three months after non-metastatic colorectal cancer diagnosis in older patients: A multi-centre prospective observational study. <i>Journal of Geriatric Oncology</i> , 2022, 13, 74-81.	1.0	4
2	Preoperative predictors for early and very early disease recurrence in patients undergoing resection of pancreatic ductal adenocarcinoma. <i>Hpb</i> , 2022, 24, 535-546.	0.3	9
3	Detection, Treatment, and Survival of Pancreatic Cancer Recurrence in the Netherlands. <i>Annals of Surgery</i> , 2022, 275, 769-775.	4.2	32
4	Impact of Dose-Escalated Chemoradiation on Quality of Life in Patients With Locally Advanced Rectal Cancer: 2-Year Follow-Up of the Randomized RECTAL-BOOST Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 694-703.	0.8	5
5	Intrafraction pancreatic tumor motion patterns during ungated magnetic resonance guided radiotherapy with an abdominal corset. <i>Physics and Imaging in Radiation Oncology</i> , 2022, 21, 1-5.	2.9	11
6	Online adaptive MR-guided stereotactic radiotherapy for unresectable malignancies in the upper abdomen using a 1.5T MR-linac. <i>Acta Oncologica</i> , 2022, 61, 111-115.	1.8	26
7	Most patients reported positively or neutrally of having served as controls in the trials within cohorts design. <i>Journal of Clinical Epidemiology</i> , 2022, 148, 39-47.	5.0	6
8	Nationwide Validation of the 8th American Joint Committee on Cancer TNM Staging System and Five Proposed Modifications for Resected Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2022, 29, 5988-5999.	1.5	11
9	ASO Visual Abstract: Nationwide Validation of the 8th American Joint Committee on Cancer TNM Staging System and Five Proposed Modifications for Resected Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2022, , .	1.5	0
10	Impact of magnetic resonance-guided versus conventional radiotherapy workflows on organ at risk doses in stereotactic body radiotherapy for lymph node oligometastases. <i>Physics and Imaging in Radiation Oncology</i> , 2022, 23, 66-73.	2.9	5
11	Dosimetric feasibility of hypofractionation for SBRT treatment of lymph node oligometastases on the 1.5T MR-linac. <i>Radiotherapy and Oncology</i> , 2021, 154, 243-248.	0.6	9
12	Oncology patients were found to understand and accept the Trials within Cohorts design. <i>Journal of Clinical Epidemiology</i> , 2021, 130, 135-142.	5.0	7
13	Impact of a vacuum cushion on intrafraction motion during online adaptive MR-guided SBRT for pelvic and para-aortic lymph node oligometastases. <i>Radiotherapy and Oncology</i> , 2021, 154, 110-117.	0.6	11
14	A field strength independent MR radiomics model to predict pathological complete response in locally advanced rectal cancer. <i>Radiologia Medica</i> , 2021, 126, 421-429.	7.7	67
15	Online adaptive MR-guided radiotherapy for rectal cancer; feasibility of the workflow on a 1.5T MR-linac: clinical implementation and initial experience. <i>Radiotherapy and Oncology</i> , 2021, 154, 172-178.	0.6	58
16	MR-Guided Radiotherapy for Rectal Cancer: Current Perspective on Organ Preservation. <i>Frontiers in Oncology</i> , 2021, 11, 619852.	2.8	27
17	Magnetic Resonance Guided Radiation Therapy for Pancreatic Adenocarcinoma, Advantages, Challenges, Current Approaches, and Future Directions. <i>Frontiers in Oncology</i> , 2021, 11, 628155.	2.8	27
18	Patterns of Care, Tolerability, and Safety of the First Cohort of Patients Treated on a Novel High-Field MR-Linac Within the MOMENTUM Study: Initial Results From a Prospective Multi-Institutional Registry. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 867-875.	0.8	37

#	ARTICLE	IF	CITATIONS
19	Progression-free survival in patients with <sup>68</sup> Ga-PSMA-PET-directed SBRT for lymph node oligometastases. <i>Acta Oncologica</i> , 2021, 60, 1342-1351.	1.8	9
20	Planning target volume margin assessment for online adaptive MR-guided dose-escalation in rectal cancer on a 1.5T MR-Linac. <i>Radiotherapy and Oncology</i> , 2021, 162, 150-155.	0.6	18
21	Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancer: Chemotherapy or Chemoradiotherapy?. <i>Frontiers in Oncology</i> , 2021, 11, 744161.	2.8	5
22	Predicting the tumor response to chemoradiotherapy for rectal cancer: Model development and external validation using MRI radiomics. <i>Radiotherapy and Oncology</i> , 2020, 142, 246-252.	0.6	61
23	The trials within cohorts design facilitated efficient patient enrollment and generalizability in oncology setting. <i>Journal of Clinical Epidemiology</i> , 2020, 120, 33-39.	5.0	25
24	Patient-Reported Work Ability During the First Two Years After Rectal Cancer Diagnosis. <i>Diseases of the Colon and Rectum</i> , 2020, 63, 578-587.	1.3	12
25	The MOMENTUM Study: An International Registry for the Evidence-Based Introduction of MR-Guided Adaptive Therapy. <i>Frontiers in Oncology</i> , 2020, 10, 1328.	2.8	81
26	Efficacy of Dose-Escalated Chemoradiation on Complete Tumor Response in Patients with Locally Advanced Rectal Cancer (RECTAL-BOOST): A Phase 2 Randomized Controlled Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 1008-1018.	0.8	51
27	Target coverage and dose criteria based evaluation of the first clinical 1.5T MR-linac SBRT treatments of lymph node oligometastases compared with conventional CBCT-linac treatment. <i>Radiotherapy and Oncology</i> , 2020, 146, 118-125.	0.6	43
28	The effect of neoadjuvant short-course radiotherapy and delayed surgery versus chemoradiation on postoperative outcomes in locally advanced rectal cancer patients – A propensity score matched nationwide audit-based study. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1605-1612.	1.0	4
29	Radiotherapy quality assurance for mesorectum treatment planning within the multi-center phase II STAR-TReC trial: Dutch results. <i>Radiation Oncology</i> , 2020, 15, 41.	2.7	3
30	Individual lymph nodes: “See it and Zap it”. <i>Clinical and Translational Radiation Oncology</i> , 2019, 18, 46-53.	1.7	23
31	MRI-based tumor inter-fraction motion statistics for rectal cancer boost radiotherapy. <i>Acta Oncologica</i> , 2019, 58, 232-236.	1.8	14
32	Health-related quality of life in rectal cancer patients undergoing neoadjuvant chemoradiation with delayed surgery versus short-course radiotherapy with immediate surgery: a propensity score-matched cohort study. <i>Acta Oncologica</i> , 2019, 58, 407-416.	1.8	18
33	The effect of time interval from chemoradiation to surgery on postoperative complications in patients with rectal cancer. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1584-1591.	1.0	3
34	Adaptive radiotherapy: The Elekta Unity MR-linac concept. <i>Clinical and Translational Radiation Oncology</i> , 2019, 18, 54-59.	1.7	330
35	Gross Tumor Delineation in Esophageal Cancer on MRI Compared With 18F-FDG-PET/CT. <i>Advances in Radiation Oncology</i> , 2019, 4, 596-604.	1.2	11
36	Feasibility of stereotactic radiotherapy using a 1.5T MR-linac: Multi-fraction treatment of pelvic lymph node oligometastases. <i>Radiotherapy and Oncology</i> , 2019, 134, 50-54.	0.6	116

#	ARTICLE	IF	CITATIONS
37	Systematic review on the role of serum tumor markers in the detection of recurrent pancreatic cancer. <i>Hpb</i> , 2018, 20, 297-304.	0.3	46
38	Effect of Neoadjuvant Therapy and Rectal Surgery on Health-related Quality of Life in Patients With Rectal Cancer During the First 2 Years After Diagnosis. <i>Clinical Colorectal Cancer</i> , 2018, 17, e499-e512.	2.3	58
39	Comparison of pathological complete response rates after neoadjuvant short-course radiotherapy or chemoradiation followed by delayed surgery in locally advanced rectal cancer. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1013-1017.	1.0	31
40	Development and validation of an MRI-based model to predict response to chemoradiotherapy for rectal cancer. <i>Radiotherapy and Oncology</i> , 2018, 126, 437-442.	0.6	21
41	Systematic review on the impact of pancreatoduodenectomy on quality of life in patients with pancreatic cancer. <i>Hpb</i> , 2018, 20, 204-215.	0.3	50
42	Does setup on rectal wall improve rectal cancer boost radiotherapy?. <i>Radiation Oncology</i> , 2018, 13, 61.	2.7	4
43	Utility Scores and Preferences for Surgical and Organ-Sparing Approaches for Treatment of Intermediate and High-Risk Rectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2018, 61, 911-919.	1.3	12
44	Tolerability, Safety, and Outcomes of Neoadjuvant Chemoradiotherapy With Capecitabine for Patients Aged $\geq 70$ Years With Locally Advanced Rectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, 179-186.	2.3	6
45	The impact of postoperative complications on health-related quality of life in older patients with rectal cancer; a prospective cohort study. <i>Journal of Geriatric Oncology</i> , 2018, 9, 102-109.	1.0	41
46	Tumor volume regression during preoperative chemoradiotherapy for rectal cancer: a prospective observational study with weekly MRI. <i>Acta Oncologica</i> , 2018, 57, 723-727.	1.8	31
47	Long-term health-related quality of life after pancreatic resection for malignancy in patients with and without severe postoperative complications. <i>Hpb</i> , 2018, 20, 188-195.	0.3	38
48	Feasibility of magnetic resonance imaging-only rectum radiotherapy with a commercial synthetic computed tomography generation solution. <i>Physics and Imaging in Radiation Oncology</i> , 2018, 7, 58-64.	2.9	22
49	Imaging predictors of treatment outcomes in rectal cancer: An overview. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 129, 153-162.	4.4	17
50	The diagnostic performance of CT versus FDG PET-CT for the detection of recurrent pancreatic cancer: a systematic review and meta-analysis. <i>European Journal of Radiology</i> , 2018, 106, 128-136.	2.6	53
51	Dose evaluation of fast synthetic-CT generation using a generative adversarial network for general pelvis MR-only radiotherapy. <i>Physics in Medicine and Biology</i> , 2018, 63, 185001.	3.0	188
52	Abstract CT067: The Prospective Dutch ColoRectal Cancer Cohort (PLCRC): a prospective nationwide observational cohort study providing the infrastructure for registry based trials. , 2017, , .		0
53	Diffusion-weighted MRI for Early Prediction of Treatment Response on Preoperative Chemoradiotherapy for Patients With Locally Advanced Rectal Cancer. <i>Annals of Surgery</i> , 2016, 263, 522-528.	4.2	34
54	Evolution of motion uncertainty in rectal cancer: implications for adaptive radiotherapy. <i>Physics in Medicine and Biology</i> , 2016, 61, 1-11.	3.0	30

#	ARTICLE	IF	CITATIONS
55	OC-0365: The need for anatomical landmarks in adaptive rectal cancer boost radiotherapy. <i>Radiotherapy and Oncology</i> , 2016, 119, S169-S170.	0.6	0
56	Inter-observer agreement of MRI-based tumor delineation for preoperative radiotherapy boost in locally advanced rectal cancer. <i>Radiotherapy and Oncology</i> , 2016, 118, 399-407.	0.6	33
57	PD-0455: Combined T2w volumetry, DW-MRI and DCE-MRI for response assessment after chemoradiation in rectal cancer. <i>Radiotherapy and Oncology</i> , 2015, 115, S223.	0.6	1
58	Randomized controlled trial for pre-operative dose-escalation BOOST in locally advanced rectal cancer (RECTAL BOOST study): study protocol for a randomized controlled trial. <i>Trials</i> , 2015, 16, 58.	1.6	55
59	PO-0784: Rectal tumor volume shrinkage evaluated with MRI during preoperative chemoradiotherapy. <i>Radiotherapy and Oncology</i> , 2015, 115, S391-S392.	0.6	0
60	Combined T2w volumetry, DW-MRI and DCE-MRI for response assessment after neo-adjuvant chemoradiation in locally advanced rectal cancer. <i>Acta Oncologica</i> , 2015, 54, 1729-1736.	1.8	48
61	Dynamic contrast enhanced MR imaging for rectal cancer response assessment after neo-adjuvant chemoradiation. <i>Journal of Magnetic Resonance Imaging</i> , 2015, 41, 1646-1653.	3.4	82
62	OC-0049: Dynamic contrast enhanced MR imaging for rectal cancer response assessment after neo-adjuvant chemoradiation. <i>Radiotherapy and Oncology</i> , 2014, 111, S18.	0.6	1
63	Statistical Modeling of CTV Motion and Deformation for IMRT of Early-Stage Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 664-672.	0.8	15
64	Impact of radiotherapy boost on pathological complete response in patients with locally advanced rectal cancer: A systematic review and meta-analysis. <i>Radiotherapy and Oncology</i> , 2014, 113, 1-9.	0.6	124
65	Repeatability of diffusion-weighted imaging in rectal cancer. <i>Journal of Magnetic Resonance Imaging</i> , 2014, 40, 146-150.	3.4	25
66	OC-0574: MRI-based inter-fraction motion analysis for rectal cancer boost radiotherapy. <i>Radiotherapy and Oncology</i> , 2014, 111, S224-S225.	0.6	2
67	Diffusion-weighted MRI in locally advanced rectal cancer. <i>Strahlentherapie Und Onkologie</i> , 2013, 189, 117-122.	2.0	87
68	Kidney motion during free breathing and breath hold for MR-guided radiotherapy. <i>Physics in Medicine and Biology</i> , 2013, 58, 2235-2245.	3.0	27
69	PD-0412: Repeatability of diffusion weighted imaging in rectal cancer. <i>Radiotherapy and Oncology</i> , 2013, 106, S158-S159.	0.6	0
70	Target volume delineation variation in radiotherapy for early stage rectal cancer in the Netherlands. <i>Radiotherapy and Oncology</i> , 2012, 102, 14-21.	0.6	62
71	OC-0023 GATED MRI-LINAC (MRL) TREATMENT FOR KIDNEYS: INTER BREATH HOLD VARIATIONS. <i>Radiotherapy and Oncology</i> , 2012, 103, S8.	0.6	0
72	PD-0565 DIFFUSION-WEIGHTED MR IMAGING FOR PATIENT SELECTION FOR ORGAN-SPARING TREATMENT IN LOCALLY ADVANCED RECTAL CANCER. <i>Radiotherapy and Oncology</i> , 2012, 103, S226.	0.6	0

#	ARTICLE	IF	CITATIONS
73	446 poster REPRODUCIBILITY STUDY OF DIFFUSION-WEIGHTED IMAGING IN RECTAL CANCER.. Radiotherapy and Oncology, 2011, 99, S180.	0.6	0